- Processing Solutions
- Agitators
- Asset Management
- Automation
- Blowers & Fans
- Centrifuges
- Chillers
- Compressors
- Conveyors
- Dryers & Evaporators
- Feeders
- Filtration & Separation
- Flowmeters
- Fluid Flow
- Heat Exchangers
- Instrumentation
- Level Measurement
- Maintenance & Safety
- Mixing & Blending
- Motors & Drives
- Oil Skimmers
- Piping & Tubing
- Packaging Equipment
- Powder & Bulk Solids
- Process Control
- Pumps & Seals
- Size Reduction
- Tanks & Vessels
- Valves & Actuators
- Weighing
- More
- Newsletters
- White Papers
- Buyer's Guide
- Videos
- Events
- Advertise
Mylan Inc. said its Matrix Laboratories unit received Food and Drug Administration approval to market a generic version of Pfizer Inc.''s drug Neurontin, according to the Associated Press. Neurontin was originally approved as a treatment for seizures and more recently cleared for pain caused by shingles. The generic name for the drug is gabapentin. Mylan received approval to market 100-milligram, 300-milligram, and 400-milligram doses of the capsules. The company said the drug had $300 million in sales for the 12-month period ending Dec. 31, according to IMS Health. Mylan plans to launch the generic version immediately.
More